BCDA vs VCEL vs RCKT vs NVCR

For growth investors, Vericel Corporation (VCEL) is the stronger pick with 16.

5% revenue growth year-over-year, versus -87. 8% for BioCardia, Inc. (BCDA). Vericel Corporation (VCEL) offers the better valuation at 104. 6x trailing P/E (72. 2x forward), making it the more compelling value choice. Analysts rate Vericel Corporation (VCEL) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Vericel Corporation (VCEL) delivered a total return of -32.

7%, compared to -99. 3% for BioCardia, Inc. (BCDA). Over 10 years, the gap is even starker: VCEL returned +1144% versus BCDA's -99. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), BioCardia, Inc.

(BCDA) is the lower-risk stock at 1. 11β versus NovoCure Limited's 2. 15β — meaning NVCR is approximately 93% more volatile than BCDA relative to the S&P 500. On balance sheet safety, Rocket Pharmaceuticals, Inc. (RCKT) carries a lower debt/equity ratio of 9% versus 114% for BioCardia, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Vericel Corporation (VCEL) is pulling ahead at 16.

5% versus -87. 8% for BioCardia, Inc. (BCDA). On earnings-per-share growth, the picture is similar: BioCardia, Inc. grew EPS 64. 6% year-over-year, compared to 21. 8% for NovoCure Limited. Over a 3-year CAGR, VCEL leads at 18. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Vericel Corporation (VCEL) is the more profitable company, earning 6.

0% net margin versus -137. 0% for BioCardia, Inc. — meaning it keeps 6. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: VCEL leads at 4. 0% versus -137. 9% for BCDA. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for NVCR: 87.

3% to $33. 50.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Vericel Corporation (VCEL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+1144% 10Y return).

NovoCure Limited (NVCR) carries a higher beta of 2. 15 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (VCEL: +1144%, NVCR: +38. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: BCDA is a small-cap quality compounder stock; VCEL is a small-cap high-growth stock; RCKT is a small-cap quality compounder stock; NVCR is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.